Unknown

Dataset Information

0

Inhibition of adaptive immunity by IL9 can be disrupted to achieve rapid T-cell sensitization and rejection of progressive tumor challenges.


ABSTRACT: The tolerogenic cytokine IL9 promotes T regulatory cell function and allergic airway inflammation, but it has not been extensively studied in cancer. In this report, we used IL9-deficient mice to investigate the effects of IL9 in multiple models of breast and colon cancer development. Eliminating endogenous IL9 enabled sensitization of host T cells to tumors, leading to their early rejection without the requirement of vaccines or immunomodulatory therapies. Notably, IL9-deficient mice acquired immunologic memory, which actively protected from residual disease and tumor rechallenge, an effect linked to activation of CD8(+) T cells. Depletion of either CD8(+) or CD4(+) T cells abolished the benefits of IL9 loss to tumor control. Adoptive transfer experiments showed that T cells from tumor-rejecting IL9-deficient mice retained their effector competency in wild-type animals. Moreover, neutralizing IL9 antibody phenocopied the effects of IL9 gene deletion by slowing tumor progression in wild-type animals. Our results show the ability of IL9 to function as an inhibitor of adaptive immunity that prevents the formation of immunologic memory to a growing tumor, highlighting the potential for IL9 neutralization as a unique tool for cancer immunotherapy.

SUBMITTER: Hoelzinger DB 

PROVIDER: S-EPMC4254354 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Inhibition of adaptive immunity by IL9 can be disrupted to achieve rapid T-cell sensitization and rejection of progressive tumor challenges.

Hoelzinger Dominique B DB   Dominguez Ana Lucia AL   Cohen Peter A PA   Gendler Sandra J SJ  

Cancer research 20141008 23


The tolerogenic cytokine IL9 promotes T regulatory cell function and allergic airway inflammation, but it has not been extensively studied in cancer. In this report, we used IL9-deficient mice to investigate the effects of IL9 in multiple models of breast and colon cancer development. Eliminating endogenous IL9 enabled sensitization of host T cells to tumors, leading to their early rejection without the requirement of vaccines or immunomodulatory therapies. Notably, IL9-deficient mice acquired i  ...[more]

Similar Datasets

| S-EPMC7349973 | biostudies-literature
| S-EPMC4471143 | biostudies-literature
| S-EPMC6946664 | biostudies-literature
| S-EPMC4492284 | biostudies-literature
| S-EPMC9022790 | biostudies-literature
| S-EPMC4645392 | biostudies-literature
2015-01-29 | E-GEOD-56017 | biostudies-arrayexpress
| S-EPMC5964833 | biostudies-other
| S-EPMC4564120 | biostudies-literature
| S-EPMC7598904 | biostudies-literature